If you have protein in the urine and African descent, Hispanic or American Indian you might have a gene call APOL1 contributing kidney disease. This study will test if you have change in the gene. If you do have that change you can participate in this study .

The purpose of this study is to find the maximum tolerated dose and the recommended Phase 2 dose of IOV-3001 infusion given after lifileucel to participants with advanced (unresectable or metastatic) melanoma who meet the requirements for treatment with lifileucel. The study duration for each participant will be up to about 6 months (Phase 1, Part 1) or 5 years (Phase 1, Part 2) after the lifileucel dose. Study intervention begins with surgery to get a tumor sample that will be used to make lifileucel

Do you have depression and are currently experiencing depression symptoms? We are conducting a treatment trial to see whether non-invasive brain stimulation that matches your brain waves can improve depression symptoms. This is a randomized controlled trial where participants will be randomly assigned to receive active or placebo (fake) stimulation. Compensation is provided.

Have you been diagnosed with Molecular Low-Risk Early-Stage Breast Cancer? If so, you may be able to take part in a research study using lower dose of tamoxifen, to evaluate if it is a better treatment than usual hormonal therapy in women with low-risk, early-stage breast cancer.

Are you an adult with an intellectual disability (ID/D) age 18 to 30 years? Would you and your adult care partner like to participate in a one-hour zoom interview together to answer questions that can help researchers learn about school and community experiences and technology use that helps people with ID/D transition to adulthood? Digitial gift card compensation provided to both participants.

The purpose of this study is to estimate the probability of participants being off all anti-cancer treatment (with the exception of endocrine therapy for those with ER+ disease) and free of disease progression 4 years from study entry.

Do you have lupus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopathy (IIM)? You may be eligible for a new CAR-T therapy conducted at University of North Carolina at Chapel Hill. Please reach out to learn more about this new innovative treatment.

Are you a woman with a history of breast cancer (Stage 0-III)? Do you identify as Black/African-American? Do you struggle with fear or worry that your cancer may return? If you are a breast cancer survivor that identifies as Black/African-American, you may be eligible to participate in the FoRtitude Interview Study. Compensation provided.

The purpose of this study is to test the safety and eff ectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan; or datopotamab deruxtecan followed by trastuzumab deruxtecan) to learn whether the treatment works in treating your type of cancer. Additional information collected from this study may also help inform the future use of these drugs.

Do you have metastatic or incurable, recurrent head and neck cancer? If so, you may be able to participate in a research study to find out if a new investigational drug, in combination with pembrolizumab, can help people with advanced head and neck cancer.